World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
42245
World Ranking
8829
National Ranking
4549

John P. Leonard publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John P. Leonard sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 660 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John P. Leonard D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John P. Leonard sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John P. Leonard is affiliated with Cornell University in the United States and has made significant contributions in the field of medicine, focusing particularly on pathology and forensic medicine, oncology, genetics, molecular biology, and neurology.

Their main research topics include lymphoma diagnosis and treatment, chronic lymphocytic leukemia research, CAR-T cell therapy research, CNS lymphoma diagnosis and treatment, viral-associated cancers and disorders, lung cancer treatments and mutations, and acute lymphoblastic leukemia research.

John P. Leonard has authored numerous papers, including recent publications such as:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee, 2022, Blood
  • Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures, 2021, Cancer Discovery
  • CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema, 2024, New England Journal of Medicine
  • Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma, 2024, New England Journal of Medicine
  • Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001, 2020, Journal of Clinical Oncology

The regular publication venues for their work include Blood, Journal of Clinical Oncology, Blood Advances, Hematological Oncology, and Clinical Lymphoma Myeloma & Leukemia.

Frequent co-authors collaborating with John P. Leonard are:

  • Brad S. Kahl
  • Nancy L. Bartlett
  • Jonathan W. Friedberg
  • Peter Martin
  • Sarah C. Rutherford

Their publication record spans multiple subfields, with notable activity in pathology and forensic medicine, oncology, genetics, molecular biology, and neurology. The majority of their research is categorized under medicine, where they have contributed to over 340 publications.

Best Publications

  • Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    Roland Schmitz;George W. Wright;Da Wei Huang;Calvin A. Johnson

  • Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    Anas Younes;Nancy L Bartlett;John P Leonard;Dana A Kennedy

  • CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

    Julian D. Gillmore;Ed Gane;Jorg Taubel;Justin Kao

  • Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    Wyndham H Wilson;Owen A O'Connor;Myron S Czuczman;Ann S LaCasce

  • Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

    John P. Leonard;Matthew L. Sherman;Gerald L. Fisher;Lynn J. Buchanan

  • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

    Jonathan W. Friedberg;Jeff Sharman;John Sweetenham;Patrick B. Johnston

  • Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

    Richard I. Fisher;Steven H. Bernstein;Brad S. Kahl;Benjamin Djulbegovic

  • Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Richard L. Piekarz;Robin Frye;Maria Turner;John J. Wright

  • Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas

    M. S. Kaminski;A. D. Zelenetz;O. W. Press;M. Saleh

  • Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

    J P Leonard;K E Waldburger;S J Goldman

  • Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.

    Bruce D. Cheson;John P. Leonard

  • PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease

    Lale Kostakoglu;Morton Coleman;John P. Leonard;Ichiei Kuji

  • The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

    Nichola Cooper;Roberto Stasi;Susanna Cunningham-Rundles;Michael A. Feuerstein

  • Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

    Peter Martin;Amy Chadburn;Paul Christos;Karen Weil

  • Cutting Edge: Identification of GL50, a Novel B7-Like Protein That Functionally Binds to ICOS Receptor

    Vincent Ling;Paul W. Wu;Heather F. Finnerty;Kevin M. Bean

  • Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

    A. Goy;S. H. Bernstein;B. S. Kahl;B. Djulbegovic

  • Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

    Jia Ruan;Peter Martin;Richard R. Furman;Shing M. Lee

  • Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.

    Michael J. Eppihimer;Jason Gunn;Gordon J. Freeman;Edward A. Greenfield

  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    Nancy L. Bartlett;Wyndham H. Wilson;Sin Ho Jung;Eric D. Hsi

  • Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.

    Brad S. Kahl;Nancy L. Bartlett;John P. Leonard;Ling Chen

Frequent Co-Authors

Morton Coleman
Morton Coleman Cornell University
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Bruce D. Cheson
Bruce D. Cheson Georgetown University
Selina Chen-Kiang
Selina Chen-Kiang Cornell University
Eric D. Hsi
Eric D. Hsi Cleveland Clinic
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Paul J. Christos
Paul J. Christos Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean becoming a physician. There are numerous online degree pathways designed to help students and working professionals advance in the healthcare sector. For those interested in healthcare leadership, online mha programs cahme accredited offer rigorous, recognized curriculums that prepare graduates for high-level administrative roles.

Nursing professionals seeking a faster route to career advancement can explore options like the rn to bsn without clinicals programs. These allow RNs to earn their BSN degrees online, often without on-site clinical requirements, which can be ideal for those needing flexibility.

Advanced nursing degrees are also available online, enabling nurses to move into leadership, education, or specialized clinical roles. For those wanting to earn a doctorate in the shortest possible time, the quickest dnp program options provide accelerated completion. Alternatively, nurses looking for less intensive routes might prefer the online dnp programs that balance academic requirements with manageable workloads.

Best Scientists Citing John P. Leonard

Trending Scientists